智通财经APP获悉，据媒体周一报道，礼来公司(LLY.US)正在就收购基因编辑初创企业Verve Therapeutics (VERV.US)进行深入谈判，交易金额最高可达 13 亿美元，此举旨在强化其实验性药物的研发管线。该交易最快可能在本周宣布，前提是谈判能够顺利进行下去。消息公布，截至发稿，Verve Therapeutics股价盘后大涨74.8%。
该制药公司的收购报价包括一次性支付近 10 亿美元用于收购Verve Therapeutics ，此外还根据这家基因药物公司的某些临床进展目标达成情况再支付 3 亿美元。
Verve Therapeutics目前正在研发一种基因疗法，旨在降低高胆固醇水平，该疗法预计将与其他药物联合使用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.